Senate Bill No. introduced by M. Yakawich aims to restrict the use of state funds for purchasing opioid overdose reversal drugs, specifically prohibiting such purchases from entities involved in settlements related to the manufacture, sale, or distribution of prescription opioids after June 30, 2025. The bill stipulates that state funds or federal funding cannot be used to buy opioid antagonists from these entities, although existing contracts executed before July 1, 2025, will remain valid until their terms are fulfilled. Additionally, any state contracts with these entities cannot be renewed after the specified date.

The bill also includes provisions that require individuals or entities that have previously agreed to provide opioid antagonists as part of a settlement with the state to continue fulfilling their obligations until the settlement terms are completed. The term "opioid antagonist" is defined in accordance with existing law. The bill is set to take effect immediately upon passage and approval, and it is intended to be codified as part of Title 18, chapter 1, part 1 of the Montana Code.